Table Info

Table 1.

Laboratory tests

Labs	Values	Labs	Values
Hemoglobin	10.3 g/dL	Bicarbonates	23.8 mEq/L
Hematocrit	32%	Calcium	7.9 mg/dL
RBC	3.51 × 10⁶ per mcL	Magnesium	1.8 mg/dL
WBC	5 × 10³ per mcL	Uric acid	7.1 mg/dL
Platelets	226 × 10³ per mcL	Cholesterol	229 mg/dL
Urea	107 mg/dL	Triglycerides	472 mg/dL
Creatinine	3.7 mg/dL	Albumin	1.7 g/dL
Na	140 mEq/L	CRP	0.2 mg/L
K	6.7 mmol/L	Glucose	99 mg/dL
Cl	111 mEq/L	Liver enzymes	Normal

RBC: red blood cell; WBC: white blood cell; CRP: C-reactive protein

Declarations

Author contributions

VN, RC and JF wrote the first draft of the manuscript. JAN, SB and BBA helped with collection of data. CG was the pathologist who interpreted biopsy results. All authors contributed to revision of manuscript, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Written informed consent was obtained from the patient.

Consent to publication

Not applicable.

Availability of data and materials

All relevant data are contained within the manuscript.

Funding

Not applicable.

Copyright

References

Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6:103–10. [DOI] [PubMed]

Devasahayam J, Erode-Singaravelu G, Bhat Z, Oliver T, Chandran A, Zeng X, et al. C1q nephropathy: the unique underrecognized pathological entity. Anal Cell Pathol (Amst). 2015;2015:490413. [DOI] [PubMed] [PMC]

Mii A, Shimizu A, Masuda Y, Fujita E, Aki K, Ishizaki M, et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol. 2009;13:263–74. [DOI] [PubMed]

Malleshappa P, Ranganath R, Chaudhari AP, Ayiangar A, Lohitaksha S. C1q nephropathy presenting as acute renal failure. Saudi J Kidney Dis Transpl. 2011;22:324–6. [PubMed]

Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751–2. [DOI] [PubMed]

C1q Nephropathy [Internet]. Chapel Hill: UNC Kidney Center; [cited 2021 Feb 20]. Available from: https://unckidneycenter.org/kidneyhealthlibrary/glomerular-disease/c1q-nephropathy/

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:753–79. [DOI] [PubMed]

Shimizu A, Higo S, Fujita E, Mii A, Kaneko T. Focal segmental glomerulosclerosis after renal transplantation. Clin Transplant. 2011;25 Suppl 23:6–14. [DOI] [PubMed]

Nehus EJ, Goebel JW, Succop PS, Abraham EC. Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation. 2013;96:550–4. [DOI] [PubMed]

10.

Panuncio A, Alba A, Bacigalupe C, Caorsi H, Schwedt E, Otatti G, et al. Nefropatía C1q en un paciente de 17 años. Caso clínico. Rev Med Chil. 2008;136:1307–10. Spanish. [DOI] [PubMed]

11.

Zhao Y, Fan H, Bao BY, Liu T, You XQ, Li GF. C1q nephropathy in an old woman with acute renal failure: a case report and literature review. Ren Fail. 2014;36:1136–8. [DOI] [PubMed]

12.

Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The effects of high-protein diets on kidney health and longevity. J Am Soc Nephrol. 2020;31:1667–79. [DOI] [PubMed] [PMC]